Rectal Spacer Impact on Clinical Outcomes in Prostate RT

Martin T. King, MD, PhD, explains why his hypofractionated rectal spacer trial pushed for state-of-the-art radiotherapy in both arms, a design choice built to isolate the spacer's true clinical benefit.

Martin T. King, MD, PhD, unpacks why fewer grade 2 or higher GI events with rectal spacing can mean fewer colonoscopies, less rectal bleeding, and meaningful quality-of-life gains for patients weighing their radiation options.

As IMRT and image-guided techniques push precision to its limits, Martin T. King, MD, PhD, argues rectal spacers still earn their place by widening the margin between prostate and rectum.

Martin T. King, MD, PhD, compares his 3-year hyaluronic acid spacer results with prior hydrogel data and walks through the practical factors, sculpting, apical placement, reversibility, that shape his own product choice.

No periprocedural adverse events and no new late safety signals: Martin T. King, MD, PhD, explains why 3-year data reassure him about rectal spacer use in appropriately selected patients.

Martin T. King, MD, PhD, looks ahead to micro-boost radiation, SBRT, and open questions about sexual and urinary quality of life that could reshape how rectal spacers are used.